|
1
|
Black DM, Cummings SR, Karpf DB, et al:
Randomised trial of effect of alendronate on risk of fracture in
women with existing vertebral fractures Fracture Intervention Trial
Research Group. Lancet. 348:1535–1541. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Berenson JR, Hillner BE, Kyle RA, et al:
American Society of Clinical Oncology Bisphosphonates Expert Panel:
American Society of Clinical Oncology clinical practice guidelines:
The role of bisphosphonates in multiple myeloma. J Clin Oncol.
20:3719–3736. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fleisch H: Bisphosphonates: Mechanisms of
action. Endocr Rev. 19:80–100. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Russell RG, Croucher PI and Rogers MJ:
Bisphosphonates: Pharmacology, mechanisms of action and clinical
uses. Osteoporos Int. 9(Suppl 2): S66–S80. 1999.PubMed/NCBI
|
|
5
|
Löwik CW, van der Pluijm G, van der
Wee-Pals LJ, et al: Migration and phenotypic transformation of
osteoclast precursors into mature osteoclasts: the effect of a
bisphosphonate. J Bone Miner Res. 3:185–192. 1988.PubMed/NCBI
|
|
6
|
Piper K, Boyde A and Jones SJ: The effect
of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (ADP) on the
resorptive function of osteoclasts of known nuclear number. Calcif
Tissue Int. 54:56–61. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hughes DE, Wright KR, Uy HL, et al:
Bisphosphonates promote apoptosis in murine osteoclasts in vitro
and in vivo. J Bone Miner Res. 10:1478–1487. 1995.PubMed/NCBI
|
|
8
|
Reszka AA, Halasy-Nagy JM, Masarachia PJ,
et al: Bisphosphonates act directly on the osteoclast to induce
caspase cleavage of mst1 kinase during apoptosis. A link between
inhibition of the mevalonate pathway and regulation of an
apoptosis-promoting kinase. J Biol Chem. 274:34967–34973. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Diel IJ, Solomayer EF and Bastert G:
Bisphosphonates and the prevention of metastasis: first evidences
from preclinical and clinical studies. Cancer. 88:3080–3088. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pietschmann P, Stohlawetz P, Brosch S, et
al: The effect of alendronate on cytokine production, adhesion
molecule expression and transendothelial migration of human
peripheral blood mononuclear cells. Calcif Tissue Int. 63:325–330.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ledoux D, Hamma-Kourbali Y, Di Benedetto
M, et al: A new dimethyl ester bisphosphonate inhibits angiogenesis
and growth of human epidermoid carcinoma xenograft in nude mice.
Anticancer Drugs. 17:479–485. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rogers MJ, Watts DJ and Russell RG:
Overview of bisphosphonates. Cancer. 80(Suppl): 1652–1660.
1997.PubMed/NCBI
|
|
13
|
Boonyapakorn T, Schirmer I, Reichart PA,
et al: Bisphosphonate-induced osteonecrosis of the jaws:
Prospective study of 80 patients with multiple myeloma and other
malignancies. Oral Oncol. 44:857–869. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Green J and Clézardin P: The molecular
basis of bisphosphonate activity: a preclinical perspective. Semin
Oncol. 37(Suppl 1): S3–S11. 2010.PubMed/NCBI
|
|
15
|
Marx RE: Pamidronate (Aredia) and
zoledronate (Zometa) induced avascular necrosis of the jaws: A
growing epidemic. J Oral Maxillofac Surg. 61:1115–1117. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Janovská Z: Bisphosphonate-related
osteonecrosis of the jaws A severe side effect of bisphosphonate
therapy. Acta Medica (Hradec Kralove). 55:111–115. 2012.PubMed/NCBI
|
|
17
|
Ferlito S, Puzzo S, Palermo F and Verzì P:
Treatment of bisphosphonate-related osteonecrosis of the jaws:
presentation of a protocol and an observational longitudinal study
of an Italian series of cases. Br J Oral Maxillofac Surg.
50:425–429. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McLeod NM, Brennan PA and Ruggiero SL:
Bisphosphonate osteonecrosis of the jaw: A historical and
contemporary review. Surgeon. 10:36–42. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tubiana-Hulin M, Spielmann M, Roux C, et
al: Physiopathology and management of osteonecrosis of the jaws
related to bisphosphonate therapy for malignant bone lesions. A
French expert panel analysis. Crit Rev Oncol Hematol. 71:12–21.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ruggiero SL, Dodson TB, Assael LA, et al:
Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws;
American Association of Oral and Maxillofacial Surgeons. American
Association of Oral and Maxillofacial Surgeons position paper on
bisphosphonate-related osteonecrosis of the jaw − 2009 update. Aust
Endod J. 35:119–130. 2009.PubMed/NCBI
|
|
21
|
Hoff AO, Toth BB, Altundag K, et al:
Frequency and risk factors associated with osteonecrosis of the jaw
in cancer patients treated with intravenous bisphosphonates. J Bone
Miner Res. 23:826–836. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bamias A, Kastritis E, Bamia C, et al:
Osteonecrosis of the jaw in cancer after treatment with
bisphosphonates: Incidence and risk factors. J Clin Oncol.
23:8580–8587. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thumbigere-Math V, Tu L, Huckabay S, et
al: A retrospective study evaluating frequency and risk factors of
osteonecrosis of the jaw in 576 cancer patients receiving
intravenous bisphosphonates. Am J Clin Oncol. 35:386–392. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brufsky AM, Sereika SM, Mathew A, et al:
Long-term treatment with intravenous bisphosphonates in metastatic
breast cancer: A retrospective study. Breast J. 19:504–511.
2013.PubMed/NCBI
|
|
25
|
Vahtsevanos K, Kyrgidis A, Verrou E, et
al: Longitudinal cohort study of risk factors in cancer patients of
bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol.
27:5356–5362. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kos M, Kuebler JF, Luczak K and Engelke W:
Bisphosphonate-related osteonecrosis of the jaws: A review of 34
cases and evaluation of risk. J Craniomaxillofac Surg. 38:255–259.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vescovi P, Campisi G, Fusco V, et al:
Surgery-triggered and non-surgery-triggered bisphosphonate-related
osteonecrosis of the jaws (BRONJ): A retrospective analysis of 567
cases in an Italian multicentre study. Oral Oncol. 47:191–194.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Molcho S, Peer A, Berg T, et al: Diabetes
microvascular disease and the risk for bisphosphonate-related
osteonecrosis of the jaw: a single centre study. J Clin Endocrinol
Metab. 98:E1807–E1812. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wessel JH, Dodson TB and Zavras AI:
Zoledronate, smoking and obesity are strong risk factors for
osteonecrosis of the jaw: A case-control study. J Oral Maxillofac
Surg. 66:625–631. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Smidt-Hansen T, Folkmar TB, Fode K, et al:
Combination of zoledronic acid and targeted therapy is active but
may induce osteonecrosis of the jaw in patients with metastatic
renal cell carcinoma. J Oral Maxillofac Surg. 71:1532–1540. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lescaille G, Coudert AE, Baaroun V, et al:
Clinical study evaluating the effect of bevacizumab on the severity
of zoledronic acid-related osteonecrosis of the jaw in cancer
patients. Bone. 58:103–107. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fusco V, Porta C, Saia G, et al:
Osteonecrosis of the jaw in patients with metastatic renal cell
cancer treated with bisphosphonates and targeted agents: Results of
an Italian multicenter study and review of the literature. Clin
Genitourin Cancer. Dec 9–2014.(Epub ahead of print).
|
|
33
|
McKay RR, Lin X, Perkins JJ, et al:
Prognostic significance of bone metastases and bisphosphonate
therapy in patients with renal cell carcinoma. Eur Urol.
66:502–509. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
McArthur HL, Estilo C, Huryn J, Williams
T, Fornier M, Traina TA, Howard J, Hudis CA and Dickler MN:
Osteonecrosis of the jaw (ONJ) among intravenous (IV)
bisphosphonate- and/or bevacizumab-treated patients (pts) at
Memorial Sloan-Kettering Cancer Center (MSKCC). J Clin Oncol.
26:95882008.
|
